Tag Archive for: CNS

Synendos Therapeutics AG Co-Founder and SAB Member, Professor Jürg Gertsch, Presents Groundbreaking New Findings on an Endocannabinoid Transporter at Cannabinoid Research Conference

/in

Professor Gertsch identifies novel transport mechanism and presents new information on mode of action as part of presentation entitled ‘Identification of an Endocannabinoid Reuptake and Recycling Machinery’ Presentation forms part of 10th Gordon Research Conference on ‘Cannabinoid Function in the CNS’ held 16-21 July 2023 outside Barcelona, Spain BASEL, Switzerland – 18 July 2023 – Synendos […]

Read more

Neuraxpharm expands outside Europe into Brazil and Mexico

/in

Recently acquired Sanofi portfolio products to be combined with acquired Libber Pharma infrastructure to build new affiliate in Brazil Products in Mexico to be distributed through newly established greenfield affiliate  Barcelona and Düsseldorf – July 11, 2023 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) […]

Read more

Neuraxpharm agrees on the divestment of inhalation API specialist Inke to Keensight Capital

/in

Transaction enables Neuraxpharm to further focus on its core CNS therapeutic area and for Inke to accelerate its development as an independent entity Neuraxpharm Group (“Neuraxpharm”), the leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announced today that it has signed a binding agreement to divest Inke, a specialized inhalation active pharmaceutical […]

Read more

Neuraxpharm announces closing of acquisition of established products from Sanofi

/in

Düsseldorf and Barcelona – February 1, 2023 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the closing of the previously announced acquisition of two established product portfolios for CNS disorders, pain and vascular diseases from Sanofi. Read more…

Read more

Neuraxpharm completes its presence in the Benelux by opening an affiliate in Brussels to cover Belgium and Luxembourg

/in

Belgium team to expand under Country Manager, Dr Pierre-Hervé Brun, providing CNS treatments to patients Brussels and Düsseldorf – January 24, 2023 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the establishment of Neuraxpharm Belgium to cover Belgium and Luxembourg, completing its presence […]

Read more